Whitnell & Co. increased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 390.0% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 50,507 shares of the biopharmaceutical company’s stock after purchasing an additional 40,200 shares during the period. Whitnell & Co.’s holdings in Pfizer were worth $1,815,000 as of its most recent SEC filing.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
A number of other hedge funds have also made changes to their positions in the stock. Weybosset Research & Management LLC lifted its holdings in shares of Pfizer by 2.0% in the 2nd quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 250 shares during the period. Financial Gravity Wealth Inc. lifted its holdings in shares of Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 257 shares during the period. Intl Fcstone Inc. lifted its holdings in shares of Pfizer by 2.4% in the 2nd quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 261 shares during the period. Lee Financial Co lifted its holdings in shares of Pfizer by 6.2% in the 2nd quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 265 shares during the period. Finally, Sheets Smith Wealth Management lifted its holdings in shares of Pfizer by 0.6% in the 3rd quarter. Sheets Smith Wealth Management now owns 47,993 shares of the biopharmaceutical company’s stock valued at $1,724,000 after buying an additional 272 shares during the period. Hedge funds and other institutional investors own 71.52% of the company’s stock.
In other Pfizer news, Director Scott Gottlieb purchased 3,000 shares of Pfizer stock in a transaction that occurred on Friday, August 23rd. The stock was bought at an average price of $34.72 per share, with a total value of $104,160.00. Following the acquisition, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.
NYSE PFE traded up $0.14 during trading hours on Friday, reaching $37.05. The company’s stock had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. The firm has a market capitalization of $207.30 billion, a price-to-earnings ratio of 12.35, a P/E/G ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a 1-year low of $33.97 and a 1-year high of $46.47. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. The company’s 50-day moving average is $36.62 and its two-hundred day moving average is $39.26.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. The company had revenue of $12.68 billion during the quarter, compared to analysts’ expectations of $12.37 billion. Pfizer had a return on equity of 28.61% and a net margin of 30.57%. Pfizer’s quarterly revenue was down 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.78 EPS. Equities analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a yield of 3.89%. Pfizer’s payout ratio is 48.00%.
Several brokerages have recently issued reports on PFE. UBS Group reissued a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. Bank of America began coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price objective for the company. Credit Suisse Group reissued a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a report on Wednesday. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. Finally, DZ Bank raised Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a report on Wednesday, August 28th. Nine equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $44.02.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
See Also: Leveraged Buyout (LBO)
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).